Astragaloside II Ameliorated Podocyte Injury and Mitochondrial Dysfunction in Streptozotocin-Induced Diabetic Rats

• DOI: 10.3389/fphar.2021.638422
• Publication Date: 2021-03-16T06:47:01Z
• Authors: Jun Su; Chongting Gao; Ling Xie; Ying Fan; Yilan Shen; Qunwei Huang; Niansong Wang; Youhua Xu; Nizhi Yang; Dingkun Gui
• Keywords: MFN2; Glomerulosclerosis; PINK1; Urotensin II

Astragaloside II (AS II), a novel saponin purified from Astragalus membranes, has been reported to modulate the immune response, repair tissue injury, and prevent inflammatory response. However, protective effects of AS on podocyte injury in diabetic nephropathy (DN) have not investigated yet. In this study, we aimed investigate beneficial mitochondrial dysfunction DN. Diabetes was induced with streptozotocin (STZ) by intraperitoneal injection at 55 mg/kg rats. Diabetic rats were randomly divided into four groups, namely, treated losartan (10 mg·kg −1 ·d ) or (3.2 6.4 for 9 weeks. Normal Sprague-Dawley chosen as nondiabetic control group. Urinary albumin/creatinine ratio (ACR), biochemical parameters, renal histopathology apoptosis, morphological changes evaluated. Expressions dynamics-related autophagy-related proteins, such Mfn2, Fis1, P62, LC3, well Nrf2, Keap1, PINK1, Parkin, examined immunohistochemistry, western blot, real-time PCR, respectively. Our results indicated that ameliorated albuminuria, histopathology, foot process effacement apoptosis also partially restored expression including LC3. increased PINK1 Parkin associated mitophagy Moreover, facilitated antioxidative stress ability via increasing Nrf2 decreasing Keap1 protein level. These suggested partly through regulation pathway. important findings might provide an innovative therapeutic strategy treatment